APA (7th ed.) Citation

Lone Fjord-Larsen, Annemette Thougaard, Karen Malene Wegener, Joan Christiansen, Frank Larsen, Lise Maj Schrøder-Hansen, . . . Dorte Kornerup Ditlevsen. (2021). Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Lone Fjord-Larsen, Annemette Thougaard, Karen Malene Wegener, Joan Christiansen, Frank Larsen, Lise Maj Schrøder-Hansen, Marianne Kaarde, and Dorte Kornerup Ditlevsen. Nonclinical Safety Evaluation, Pharmacokinetics, and Target Engagement of Lu AF82422, a Monoclonal IgG1 Antibody Against Alpha-synuclein in Development for Treatment of Synucleinopathies. Taylor & Francis Group, 2021.

MLA (9th ed.) Citation

Lone Fjord-Larsen, et al. Nonclinical Safety Evaluation, Pharmacokinetics, and Target Engagement of Lu AF82422, a Monoclonal IgG1 Antibody Against Alpha-synuclein in Development for Treatment of Synucleinopathies. Taylor & Francis Group, 2021.